PL2618842T3 - Nowa metoda immunostymulacyjna - Google Patents

Nowa metoda immunostymulacyjna

Info

Publication number
PL2618842T3
PL2618842T3 PL11826223T PL11826223T PL2618842T3 PL 2618842 T3 PL2618842 T3 PL 2618842T3 PL 11826223 T PL11826223 T PL 11826223T PL 11826223 T PL11826223 T PL 11826223T PL 2618842 T3 PL2618842 T3 PL 2618842T3
Authority
PL
Poland
Prior art keywords
novel immunostimulatory
immunostimulatory method
novel
immunostimulatory
Prior art date
Application number
PL11826223T
Other languages
English (en)
Inventor
David Charles Jackson
Amabel Tan
Weiguang Zeng
Original Assignee
Ena Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010904284A external-priority patent/AU2010904284A0/en
Application filed by Ena Therapeutics Pty Ltd filed Critical Ena Therapeutics Pty Ltd
Publication of PL2618842T3 publication Critical patent/PL2618842T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL11826223T 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna PL2618842T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010904284A AU2010904284A0 (en) 2010-09-22 Novel Immunostimulatory Method
AU2011902408A AU2011902408A0 (en) 2011-06-20 Novel immunstimulatory method
PCT/AU2011/001225 WO2012037612A1 (en) 2010-09-22 2011-09-22 Novel immunostimulatory method
EP11826223.7A EP2618842B1 (en) 2010-09-22 2011-09-22 Novel immunostimulatory method

Publications (1)

Publication Number Publication Date
PL2618842T3 true PL2618842T3 (pl) 2019-10-31

Family

ID=45873313

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11826223T PL2618842T3 (pl) 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna
PL20155567.9T PL3669892T3 (pl) 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20155567.9T PL3669892T3 (pl) 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej

Country Status (10)

Country Link
US (5) US9676819B2 (pl)
EP (3) EP3520814A1 (pl)
JP (5) JP2013537892A (pl)
CN (2) CN103189072B (pl)
AU (1) AU2011305061B2 (pl)
CA (1) CA2811957C (pl)
DK (1) DK2618842T3 (pl)
ES (2) ES2735274T3 (pl)
PL (2) PL2618842T3 (pl)
WO (1) WO2012037612A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3520814A1 (en) * 2010-09-22 2019-08-07 Ena Therapeutics Pty Ltd Immunostimulating composition
CN109893648A (zh) 2013-06-28 2019-06-18 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
AU2018241248A1 (en) * 2017-03-31 2019-09-05 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
EP3727372A4 (en) * 2017-12-21 2021-10-27 Ena Therapeutics Pty Ltd ADMINISTRATION OF A TLR2 AGONIST TO TREAT OR PREVENT AN INFECTIOUS RESPIRATORY DISEASE
US20220388950A1 (en) 2019-06-26 2022-12-08 Axelia Oncology Pty Ltd Novel molecules
US20230043518A1 (en) * 2019-09-04 2023-02-09 Axelia Oncology Pty Ltd Cancer immunotherapy
EP4025203A4 (en) * 2019-09-04 2023-12-20 Axelia Oncology Pty Ltd CANCER TREATMENT

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
AU772617B2 (en) 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
CN1606446A (zh) * 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
CA2494193A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
EP1543039B1 (en) * 2002-08-12 2011-07-13 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CN1921877A (zh) * 2004-01-16 2007-02-28 悉生物有限公司 陪伴蛋白10对Toll样受体诱导的细胞因子和趋化因子分泌的调节
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
CA2593746A1 (en) * 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
WO2006084319A1 (en) 2005-02-08 2006-08-17 The Council Of The Queensland Institute Of Medical Research Immunogenic molecules
WO2006091591A1 (en) 2005-02-22 2006-08-31 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
WO2008085549A2 (en) 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
US9089508B2 (en) * 2007-10-09 2015-07-28 The University Of Melbourne Method of transfection and compositions therefor
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2010028246A2 (en) * 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
SG173617A1 (en) 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
EP2411521B1 (en) 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EP3520814A1 (en) 2010-09-22 2019-08-07 Ena Therapeutics Pty Ltd Immunostimulating composition
WO2016037240A1 (en) 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent

Also Published As

Publication number Publication date
EP3669892B1 (en) 2024-05-08
ES2735274T3 (es) 2019-12-17
EP3669892C0 (en) 2024-05-08
US20220296505A1 (en) 2022-09-22
JP2021130713A (ja) 2021-09-09
CN103189072A (zh) 2013-07-03
JP2023113902A (ja) 2023-08-16
DK2618842T3 (da) 2019-07-01
JP2019167369A (ja) 2019-10-03
JP6657507B2 (ja) 2020-03-04
CA2811957A1 (en) 2012-03-29
US20130230544A1 (en) 2013-09-05
CN105477640A (zh) 2016-04-13
CN103189072B (zh) 2018-02-09
AU2011305061B2 (en) 2016-04-14
JP2017061504A (ja) 2017-03-30
ES2980738T3 (es) 2024-10-02
CN105477640B (zh) 2019-09-17
PL3669892T3 (pl) 2024-10-07
JP7497962B2 (ja) 2024-06-11
US9676819B2 (en) 2017-06-13
JP2013537892A (ja) 2013-10-07
WO2012037612A1 (en) 2012-03-29
US20190380952A1 (en) 2019-12-19
CA2811957C (en) 2019-04-16
US11351114B2 (en) 2022-06-07
US10406100B2 (en) 2019-09-10
EP2618842B1 (en) 2019-04-24
EP3520814A1 (en) 2019-08-07
US20240050364A1 (en) 2024-02-15
EP3669892A1 (en) 2020-06-24
US11786458B2 (en) 2023-10-17
US20170246312A1 (en) 2017-08-31
EP2618842A4 (en) 2014-03-26
AU2011305061A1 (en) 2013-05-02
EP2618842A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
GB201001833D0 (en) Method
GB201011502D0 (en) Novel process
HU1000010D0 (en) Novel process
GB201007353D0 (en) Method
HU1000330D0 (en) Novel method
GB201007354D0 (en) Method
GB201009673D0 (en) Novel process
HU1000386D0 (en) Novel process
GB201009676D0 (en) Novel process
PL2618842T3 (pl) Nowa metoda immunostymulacyjna
GB201011513D0 (en) Method
ZA201304243B (en) Improved connecting method
GB201004759D0 (en) Method
GB201009671D0 (en) Novel process
GB201012148D0 (en) Method
GB201006306D0 (en) Method
GB201010855D0 (en) Method
PL2571902T3 (pl) Nowy sposób
GB201012784D0 (en) Method
GB201007207D0 (en) Method
GB201017003D0 (en) Method
GB201007522D0 (en) Method
AU2010904284A0 (en) Novel Immunostimulatory Method
GB201021940D0 (en) Method
GB201021435D0 (en) Method